In statements to the USA TODAY Network, both the University of Rochester Medical Center, or URMC, and Regeneron noted they ...

Strand Therapeutics announced on Thursday that it landed a $153 million Series B funding led by Kinnevik. The company’s ...

Strand Therapeutics raised a $153 million Series B to develop programmable mRNA therapeutics and reshape how we treat disease ...

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

GAAP revenue of $14.2 million for Q2 2025 beat analyst estimates and Revenue more than doubled year over year in the second quarter, beating analyst estimates. Net loss per share (GAAP) narrowed to ...

Intellia expects to present additional data from the ongoing Phase 1/2 study in the second half of 2025. The Company is on track to submit a Biologics License Application (BLA) in the second half of ...

Chronic spontaneous urticaria places a heavier burden on patients than atopic dermatitis and psoriasis, leading to a worse ...

An impressive array of Big Pharma backers have lined up to ensure Strand Therapeutics has the funding needed to take its mRNA ...

Officials for retailer Claire's filed for bankruptcy protection on Wednesday as its operating costs rise while demand for its ...

Apogee Therapeutics has shared positive 16-week results from a mid-stage study of its investigational anti-IL-13 antibody in ...

The biosimilars market represents a transformative segment within the global pharmaceutical industry, offering highly similar ...

In a report released yesterday, Cory Kasimov from Evercore ISI maintained a Hold rating on Moderna, with a price target of $32.00. The company’s shares closed yesterday at $27.64. Take advantage of ...